RedHill Biopharma Ltd. (RDHL) Form 424B5 — Oct 13, 2026
RedHill Biopharma filed Prospectus Supplement No. 5 to increase the capacity under its at-the-market offering with H.C. Wainwright, registering up to $2,587,409 of additional ADS sales. Each ADS represents 10,000 ordinary shares, and the ADS last traded at $0.539 on October 9, 2026.
Key figures
- Gross Proceeds
- $2,587,409 (maximum additional ATM capacity)
- Offering Price
- $0.539 per ADS (last reported sale price on October 9, 2026)
- F3 limit
- $2,637,099 (one-third of public float per General Instruction I.B.5)
- Ads ratio
- one ADS = 10,000 ordinary shares
- Public float
- $7,911,299.70
- Ads previously sold
- 54,954 ADSs for $49,690.55
- Closing price aug 31 2026
- $0.90 per ADS
- Ordinary shares outstanding non affiliates
- 87,903,331,000
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.